Therapeutic classes
|
Pharmacist Interventions
n (%)
|
Pharmacist Interventions
n (%)
|
Pharmacist Interventions
n (%)
|
|
Prior to COVID-19 (n=54) |
During COVID-19 (n=177) |
p-value |
Acetaminophen
|
6 (11.1%)
5 (9.3%)
|
31 (17.5%)
|
0.298
|
Anticoagulants |
|
17 (9.6%) |
1.000 |
Anti-depressors |
0 |
2 (1.1%) |
1.000 |
Antidiabetics |
1 (1.9%) |
2 (1.1%) |
0.552 |
Antiemetics |
1 (1.9%) |
0 |
0.234 |
Anti-histamine |
0 |
1 (0.6%) |
1.000 |
Anti-infectious |
4 (7.4%) |
36 (20.3%) |
0.038 |
Anti inflammatories |
2 (3.7%) |
4 (2.3%) |
0.626 |
Anti-parkinsonians |
0 |
1 (0.6%) |
1.000 |
Anti-platelets |
3 (5.6%) |
9 (5.1%) |
1.000 |
Cardiologic drugs |
0 |
6 (3.4%) |
0.340 |
Experimental drugs |
0 |
1 (0.6%) |
1.000 |
Laxatives |
7 (13.0%) |
7 (4.0%) |
0.023 |
Lipid lowering drugs |
4 (7.4%) |
6 (3.4%) |
0.249 |
Ophthalmic drugs |
2 (3.7%) |
4 (2.3%) |
0.626 |
Opioids |
2 (3.7%) |
11 (6.2%) |
0.738 |
Proton pump inhibitor |
6 (11.1%) |
16 (9.0%) |
0.606 |
Psycholeptics |
3 (5.6%) |
2 (1.1%) |
0.085 |
Respiratory system drugs |
0 |
2 (1.1%) |
1.000 |
Supplements |
5 (9.3%) |
13 (7.3%) |
0.772 |
Urological agents |
3 (5.6%) |
6 (3.4%) |
0.440 |